Bladder-sparing comprehensive therapy for muscle invasive bladder cancer
10.3760/cma.j.cn115396-20220923-00308
- VernacularTitle:肌层浸润性膀胱癌的保留膀胱综合治疗
- Author:
Xiaoqiang XUE
1
;
Zhigang JI
;
Yi XIE
Author Information
1. 中国医学科学院北京协和医院泌尿外科，北京 100730
- Keywords:
Urinary bladder neoplasms;
Antineoplastic combined chemotherapy protocols;
Immunosuppressive agents;
Muscle invasive bladder cancer;
Bladder-sparing treat
- From:
International Journal of Surgery
2022;49(10):649-653
- CountryChina
- Language:Chinese
-
Abstract:
Bladder cancer is one of the most common tumors of the urinary system. More than a quarter of the new bladder cancer cases in China are muscle invasive bladder cancer. The standard treatment of muscle invasive bladder cancer is radical cystectomy plus pelvic lymph node dissection. This operation has limitations such as large trauma, high postoperative complication rate and serious impact on the quality of life of patients. To control the condition of bladder cancer and improve the quality of life of patients, a comprehensive treatment and follow-up system after bladder sparing are being explored. In addition to the classic trimodal treatment which is consisted of "maximum transurethral resection of the tumor, chemotherapy and external radiotherapy" , the treating modes of single drug, multi-drug or combined chemotherapy/radiotherapy based on immune checkpoint inhibitors are in their heyday. Meanwhile, antibody-drug conjugates have been in the ascendant. The purpose of this article is to review the current situation of bladder sparing therapy for muscle invasive bladder cancer and look forward to the development direction of bladder sparing therapy in the current era of oncoimmunology.
